Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis

KANSAS CITY, Kan., Dec. 18, 2014  -- Aratana Therapeutics, Inc. (PETX), a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for companion animals, today announced positive results from its pivotal field study of AT-001 (Grapiprant), the company's innovative drug for treating pain in dogs with osteoarthritis.  In the study, dogs receiving AT-001 demonstrated improvements in pain assessment scores that were statistically significant compared to placebo (p<0.05) at a once-daily oral dose.  Aratana expects to commence commercialization upon FDA approval, which Aratana anticipates in 2016.

Juno Therapeutics Announces Pricing of Initial Public Offering

SEATTLE-- Juno Therapeutics, Inc. today announced the pricing of its initial public offering of 11,022,917 shares of common stock at a price to the public of $24.00 per share. In addition, Juno Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,653,437 shares of common stock to cover over-allotments, if any. Juno Therapeutics’ common stock is expected to begin trading on The NASDAQ Global Select Market under the symbol “JUNO” on December 19, 2014. The offering is expected to close on December 23, 2014, subject to customary closing conditions.

Tetraphase Announces Positive Top-line Results from Phase 3 IGNITE 1 Clinical Trial of Eravacycline in Complicated Intra-abdominal Infections

—Eravacycline achieves primary endpoint in first of two pivotal trials–
—Company to host conference call at 4:30 p.m. ET today –

WATERTOWN, Mass.-- Tetraphase Pharmaceuticals, Inc. (TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced positive top-line results from IGNITE 1, the Company’s Phase 3 clinical trial of eravacycline for the treatment of complicated intra-abdominal infection (cIAI) compared to ertapenem. In the trial, eravacycline met the primary endpoint of statistical non-inferiority of clinical response at the test-of-cure (TOC) visit, under the guidance set by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

OvaScience Advances All Three Fertility Treatment Options

- AUGMENT Treatment Available in Four International Regions -
- OvaPrime Treatment to be Introduced into Select International IVF Clinics by the End of 2015 -
- OvaTure Treatment, a Potential Hormone-Free Fertility Option, Progresses into Development -

CAMBRIDGE, Mass.-- OvaScience^SM (OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, today announced the Company has achieved its 2014 corporate goals to advance the AUGMENT^SM, OvaPrime^SM and OvaTure^SM treatments for patients in need of new fertility treatment options.

“We are pleased to report that we have successfully matured human egg precursor cells into eggs in vitro. This is a major milestone for the first potential hormone-free fertility option, the OvaTure treatment. We have achieved this by designing an autologous, high throughput in vitro system, which we believe will accelerate further development of the OvaTure treatment, the only hormone-free fertility option,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience.